Zobrazeno 1 - 10
of 137
pro vyhledávání: '"R, Fedorak"'
Autor:
Amanpreet Gill, Karen Madsen, Ammar Hassanzadeh Keshteli, Heekuk Park, Ambika Agrawal, Naomi Hotte, R Fedorak, Michael Laffin, Aiden Zalasky
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-11 (2019)
Scientific Reports
Scientific Reports
Western-style diets have been implicated in triggering inflammatory bowel disease activity. The aim of this study was to identify the effect of a short-term diet high in sugar on susceptibility to colitis. Adult wild-type mice were placed on chow or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a577427738ee7cd5c5bc074860c52a2
https://doaj.org/article/b9320edf6327486489fc4b53191223e5
https://doaj.org/article/b9320edf6327486489fc4b53191223e5
Publikováno v:
J Can Assoc Gastroenterol
Europe PubMed Central
Europe PubMed Central
Background Several inflammatory markers have been associated with both obesity and the risk of adverse outcomes. Studies exploring obesity as a potential risk factor in extraintestinal manifestations (EIMs) development in patients with inflammatory b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90e5489886e18d8de683bf4155bad001
https://europepmc.org/articles/PMC7958793/
https://europepmc.org/articles/PMC7958793/
Autor:
RJ Bailey, A Barkun, J Brow, M Champion, J Deneault, R Fedorak, R Keith, E Lalor, HM Macsween, N Marcon, J Mchattie, A Micflikier, P Pare, R Passi, D Patel, D Petrunia, E Shaffer, J Sidorov, S Stordy, L Sutherland, R Tanton
Publikováno v:
Canadian Journal of Gastroenterology, Vol 10, Iss 4, Pp 237-242 (1996)
Externí odkaz:
https://doaj.org/article/685ba31cf5dc4dc289d5026fec0ed902
Autor:
Brendan P. Halloran, Gilaad G. Kaplan, Kerri L. Novak, Hang Hock Shim, Remo Panaccione, Cynthia H. Seow, Shane M. Devlin, R Fedorak, H. Al-Farhan, Christopher Ma, Levinus A. Dieleman, Ahmed Al-Darmaki, Karen I. Kroeker, Jack X Q Pang
Publikováno v:
Journal of the Canadian Association of Gastroenterology. 1:185-187
BACKGROUND: Ustekinumab (UST), an anti IL12/23 inhibitor, has been recently approved for the treatment of moderate to severe Crohn’s disease (CD) in Europe and the United States. In Canada, UST has been used off-label for CD patients failing anti-T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18d0bdd33e55324131b4d89e0fd8d2c3
https://doi.org/10.1093/jcag/gwy008.108
https://doi.org/10.1093/jcag/gwy008.108
Autor:
Vivian Huang, S van Zanten, T A Cookson, Brendan P. Halloran, Reed T. Sutton, Karen Wong, Farhad Peerani, N Stern, Adriana Lazarescu, Karen I. Kroeker, R Fedorak, Levinus A. Dieleman
BACKGROUND: Physicians use therapeutic drug monitoring of adalimumab (ADA) as an optimization tool to guide patient therapy with inflammatory bowel disease (IBD). IBD consists primarily of Crohn’s disease (CD) and ulcerative colitis (UC). Presently
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e16e42992324babb631eff82e6276a6c
https://europepmc.org/articles/PMC6512604/
https://europepmc.org/articles/PMC6512604/
Autor:
Ellina Lytvyak, David Pincock, Dan Sadowski, R Fedorak, Karen I. Kroeker, Reed T. Sutton, Daniel C. Baumgart
Publikováno v:
Europe PubMed Central
BACKGROUND: Induction and maintenance of remission is a primary treatment goal for inflammatory bowel disease (IBD). Known gaps exist in adherence of practitioners to international guidelines for IBD care and, in other specialties, it has been shown
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89b8eec8356ca904cbdf622f0c9c3a25
https://europepmc.org/articles/PMC6512531/
https://europepmc.org/articles/PMC6512531/
BACKGROUND: Ulcerative colitis (UC) is a relapsing and remitting condition, characterized by inflammation and ulceration in the colon and rectum. Biologic therapies have shown to be effective in inducing and maintaining remission in patients with UC,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64a45d430759f1b7746bd1e17188d990
https://europepmc.org/articles/PMC6512701/
https://europepmc.org/articles/PMC6512701/
Autor:
M Garolera Molas, Karen Wong, Candace L. Beilman, Ellina Lytvyak, Farhad Peerani, Brendan P. Halloran, Levinus A. Dieleman, R Fedorak, Karen I. Kroeker
Publikováno v:
Europe PubMed Central
BACKGROUND: Ulcerative colitis (UC) is a chronic, relapsing and remitting condition, characterized by inflammation and ulceration limited to the colon. Treatment of UC involves long-term maintenance therapy in an attempt to maintain remission and pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a2a725e5ec2c468bc7f2c7653dd9711
https://europepmc.org/articles/PMC6512427/
https://europepmc.org/articles/PMC6512427/
Autor:
W Ma, Jae Eun Hyun, Naomi Hotte, R Fedorak, Aiden Zalasky, Michael Laffin, Karen Madsen, S Rajaruban
BACKGROUND: Population-based studies have demonstrated an association between refined sugar intake and increased incidence of inflammatory bowel disease. We have previously shown that both long- and short-term exposure to a high sugar diet in mice in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::133dec3e00eb1a8496c6650f7df50dd4
https://europepmc.org/articles/PMC6512672/
https://europepmc.org/articles/PMC6512672/
BACKGROUND: Infliximab is an anti-TNF therapy with proven efficacy for the induction and maintenance of remission in patients with Crohn’s disease (CD). An infliximab biosimilar, CT-P13 (marketed as Inflectra), has recently been introduced that cou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00e96fd9bbb8c4ae97c6a2d8e33fea3e
https://europepmc.org/articles/PMC6507792/
https://europepmc.org/articles/PMC6507792/